|本期目录/Table of Contents|

[1]王晓露,贾蒙,张缨.嵌合抗原受体T细胞药物YESCARTA在非霍奇金淋巴瘤临床治疗中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(01):64-68.[doi:10.3969/j.issn.1672-271X.2021.01.001]
　WANG Xiao-lu,JIA Meng,ZHANG Ying.Research progress of chimeric antigen receptor T cell drug YESCARTA in clinical treatment of non Hodgkin’s lymphoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(01):64-68.[doi:10.3969/j.issn.1672-271X.2021.01.001]
点击复制

嵌合抗原受体T细胞药物YESCARTA在非霍奇金淋巴瘤临床治疗中的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年01期
页码:
64-68
栏目:
综述
出版日期:
2021-01-20

文章信息/Info

Title:
Research progress of chimeric antigen receptor T cell drug YESCARTA in clinical treatment of non Hodgkin’s lymphoma
作者:
王晓露; 贾蒙; 张缨
作者单位：210029南京，江苏省中医院肿瘤科（王晓露）；4072 布里斯班，昆士兰大学（贾蒙）；210002 南京，东部战区总医院(原解放军第八一医院)病理科（张缨）
Author(s):
WANG Xiao-lu1;  JIA Meng2 ;  ZHANG Ying3
(1.Department of Oncology,the Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu, China; 2.The University of Queensland, Brisbane 4072, Australia; 3.Department of Pathology, General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu, China)
关键词:
YESCARTA; CAR-T疗法; 临床试验; 细胞治疗
Keywords:
YESCARTA;  CAR-T cell therapy;  clinical trials;  cell therapy
分类号:
R73-3
DOI:
10.3969/j.issn.1672-271X.2021.01.001
文献标志码:
A
摘要:
YESCARTA（KTE-C19）是一种抗CD19嵌合抗原受体T细胞（CAR-T）治疗药物，对于非霍奇金淋巴瘤（NHL）和急性白血病疗效显著，具有毒性作用小、安全性高的特点，被美国食品和药品管理局FDA批准作为一种二线或多线疗法治疗复发性或难治性NHL。文章主要就YESCARTA在NHL临床治疗中的研究进展进行综述，对目前YESCARTA治疗手段的优势和存在的问题进行分析，也对未来CAR-T细胞治疗的优化提供可行性建议和参考。
Abstract:
YESCARTA (axicabbtagene ciloleucel, KTE-C19) is a kind of anti-CD19 chimeric antigen receptor T cell (CAR-T) treatment drug. In clinical treatment, YESCARTA can significantly prolong the survival time of patients, suggesting its significant therapeutic effect and high safety. YESCARTA has been approved by the food and Drug Administration of the United States as a second-line or multiple line therapy for recurrent or refractory non Hodgkin’s lymphoma. This paper reviews the research progress of YESCARTA in clinical treatment of non Hodgkin’s lymphoma, analyzes the advantages and existing problems of the current treatment of YESCARTA, and provides feasible suggestions and reference for the optimization of CAR-T cell therapy in the future.

参考文献/References:

[1]Seer. Cancer stat facts：non - Hodgkin lymphoma [EB/OL].(2017 -12-21)
[2018 -01 -18].
[2]Cheson BD, Leonard JP. Monoclonal antibody therapy for B- cell non- Hodgkin’s lymphoma[J]. N Engl J Med,2008, 359(6): 613-626.
[3]Chagantis, Illidge T, Barrington S,et al. Guidelines for the management of diffuse large B- cell lymphoma[J]. Br J Haematol,2016, 174 (1):43-56.
[4]Baybutt TR, Flickinger JC Jr, Caparosa EM,et al. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors[J]. Clin Pharmacol Ther, 2019, 105(1)：71-78.
[5]Cheadle EJ, Gornall H, Baldan V, et al. CAR T cells: driving the road from the laboratory to the clinic[J]. Immunol Rev, 2014, 257 (1):91-106.
[6]Qian LL, Chen JQ, Wu XY, et al. Cell therapy’s poster child: Chimeric antigen receptor T cell therapy[J]. Chin J Biotech, 2019,35(12): 2339-2349.
[7]支黎明，姚祎，李文娟. 嵌合抗原受体T细胞功能设计与运用的研究进展[J].东南国防医药，2017，19(1）:70-75.
[8]Thistlethwaite FC, Gilham DE, Guest RD, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity[J]. Cancer Immunol Immunother,2017, 66(11):1425-1436.
[9]Turtle CJ，Riddell SR，Maloney DG. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies[J].Clin Pharmacol Ther，2016，100(3):252-258.
[10]Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma[J]. Med Lett Drugs Ther, 2018,60(1551)：e122-e123.
[11]Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti- CD19 chimeric antigen receptor[J]. Immunother, 2009, 32:689-702.
[12]Kochenderfer JN, Yu Z, Frasheri D, et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells[J]. Blood,2010,116:3875-3886.
[13]Kochenderfer JN, Wilson WH, Janik JE, et al.Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19[J]. Blood,2010,116:4099-4102.
[14]Pieper K, Grimbacher B, Eibel H. B- cell biology and development[J]. J Allergy Clin Immunol, 2013,131(4):959-971.
[15]Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy[J]. Leuk Lymphoma, 2015,18(5-6):385-397.
[16]Poe JC, Minard-colinV,Kountikov EI, et al. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice[J]. J Immunol, 2012,189(5): 2318-2325.
[17]Neelapu SS. An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non- Hodgkin lymphoma[J]. ClinAdv Hematol Oncol, 2017, 15(2):117-120.
[18]Kochenderfer JN, Dudley ME,Kassim, et al. Chemotherapy - refractory diffuse large B - cell lymphoma and indolent B - cell malignancies can be effectively treated with autologous T cells expressing an anti - CD19 chimeric antigen receptor[J]. J Clin Oncol, 2015,33(6): 540-549.
[19]Locke F, Neelapu, Bartlett, etal. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma[J]. Molecular Therapy,2017,25(1), 285 -295.
[20]De Lima Lopes G, Nahas GR. Chimeric antigen receptor T cells, a savior with a high price[J]. Chin Clin ONcol, 2018, 7(2):21.
[21]Sharpe ME. T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology[J]. Toxicol Pathol, 2018, 46(2):131-146.
[22]Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaringsafety risks and long-term impacts[J]. Drug Discov Today. 2018, 23(6)：1175-1182.
[23]Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells[J]. Cancer Lett, 2014, 343(2):172-178.
[24]Lee WL, Slutsky AS. Sepsis and endothelial permeability[J]. N EnglJ Med, 2010, 363(7)：689- 691.
[25]Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J]. N Engl JMed, 2011, 365(8):725-733.
[26]Norelli M, Camisa B, Barbiera G,et al.Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24(6): 739-748.
[27]唐家优.NK细胞相关免疫检查位点的研究进展[J].东南国防医药，2020，22(2）:183-187.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-01-26